Stefan Klein

ORCID: 0000-0002-3351-6551 · 10 papers in corpus
nonrandomized-trial
European journal of drug metabolism and pharmacokinetics ·doi:10.1007/s13318-023-00866-0

BACKGROUND: Overactive adenosine triphosphate signaling via P2X3 homotrimeric receptors is implicated in multiple conditions. To fully understand the metabolism and elimination pathways of eliapixant, a study was conducted to assess the pha…

nonrandomized-trial 2025
International journal of molecular sciences ·doi:10.3390/ijms262010177

Hypersensitized P2X3 receptor signaling has been described to play a role in several disorders, including chronic cough. The goal of our in vitro and in vivo studies was to investigate the biotransformation and the influence of CYP3A4 inhib…

rct 2025
Pharmaceuticals (Basel, Switzerland) ·doi:10.3390/ph18050758

Background/Objectives: P2X3 receptor antagonists have been suggested as a potential treatment for urogenital, respiratory and pain conditions. This first-in-human (FiH) study evaluated filapixant, a new P2X3 receptor antagonist with high re…

rct 2024
Clinical pharmacokinetics ·doi:10.1007/s40262-024-01387-y

BACKGROUND: Afferent neuronal hypersensitization via P2X3 receptor signaling has been implicated as a driver of several disorders, including refractory chronic cough, endometriosis, diabetic neuropathic pain, and overactive bladder. Eliapix…

rct 2022
British journal of clinical pharmacology ·doi:10.1111/bcp.15358

AIMS: Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080…

rct 2022
Clinical pharmacokinetics ·doi:10.1007/s40262-022-01126-1

BACKGROUND AND OBJECTIVE: There is no licensed treatment for refractory chronic cough; off-label therapies have limited efficacy and can produce adverse effects. Excessive adenosine triphosphate signaling via P2X3 receptors is implicated in…

rct 2019
Journal of clinical pharmacology ·doi:10.1002/jcph.1396

Intravaginal rings (IVRs) are an established option for continuous administration of drugs in women. The combination of anastrozole (ATZ) and levonorgestrel (LNG) in an IVR with an intended 4-week wearing period has been considered for long…

rct 2017
Journal of clinical pharmacology ·doi:10.1002/jcph.984

A study was performed to investigate the effect of an intravaginally administered antimycotic, an antibiotic, and a spermicide plus the co-usage of tampons on the pharmacokinetics (PK) of levonorgestrel (LNG) and anastrozole (ATZ) administe…

rct 2016
Human Reproduction ·doi:10.1093/humrep/dew145

STUDY QUESTION: What are suitable doses of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG), when delivered to the systemic circulation by an intravaginal ring (IVR), for further clinical development as a pot…

rct 2011
Journal of clinical pharmacology ·doi:10.1177/0091270011423664

Dienogest offers pharmacological advantages for the effective treatment of endometriosis and for use in contraception and hormone replacement therapy. This pharmacodynamic study investigated the ovulation-inhibiting effects of dienogest mon…